


The Relentless Fight Against COVID-19



From the beginning of the global COVID-19 pandemic, Pfizer and BioNTech have been relentless in our mission to fight this deadly disease. As we continue to achieve critical milestones with our COVID-19 vaccine, we thank the colleagues, researchers, clinical trial partners, participants, and their families, who have made each of these significant moments possible.



First

authorization in the world for
emergency use in ages 16+
(December 2020)



First

authorization in the world for
emergency use in ages 12-15
(May 2021)



First

full U.S. FDA approval
for ages 16+
(August 2021)

1.3 billion
doses distributed globally



More than **120 countries
and territories** reached



3 billion doses expected to be produced
in 2021 and **4 billion doses** in 2022



2 billion doses committed to low- and
middle-income countries in 2021 and 2022



We will continue to address the evolving needs of this pandemic and work to help protect more lives around the world in the weeks and months ahead by:

- ▶ Seeking global approvals of a booster dose of the vaccine for individuals 16+
- ▶ Sharing results from our pediatric clinical trial program



This emergency use of the product has not been approved or licensed by FDA, but has been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19); the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.

Please visit www.cvdvaccine-us.com for full Prescribing Information (16+ years of age) and Caregiver and Recipient Fact Sheet (12+ years of age).